Maryland Oncology Hematology, PA

Summary

Maryland Oncology Hematology, PA is a medical facility located in Columbia, Maryland. This center is recognized for care of Breast Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Cancer, Prostate Cancer and other specialties. Maryland Oncology Hematology, PA is involved with conducting 69 clinical trials across 103 conditions. There are 5 research doctors associated with this hospital, such as Kashif Ali, Mohit Narang, MD, Yousuf Gaffar, MD, and Cheryl A Aylesworth.

Top PIs

Clinical Trials running at Maryland Oncology Hematology, PA

Breast Cancer

Multiple Myeloma

Colorectal Cancer

Melanoma

Colon Cancer

Myelodysplastic Syndrome

Myelodysplastic/Myeloproliferative Neoplasms

Rectal Cancer

Cytokine Release Syndrome

Prostate Cancer

Elacestrant

for Breast Cancer

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

Recruiting

2 awards

Phase 3

3 criteria

Tucatinib + Doxil

for Breast Cancer

This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals of this study are to: * Learn how well the combination of tucatinib and Doxil works * Learn more about the side effects of the combination of tucatinib and Doxil

Recruiting

1 award

Phase 2

13 criteria

Genomic Testing

for Breast Cancer

The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.

Recruiting

1 award

N/A

3 criteria